Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.
Adult
Carcinoma, Hepatocellular
/ epidemiology
Case-Control Studies
Coinfection
/ complications
Female
Gambia
/ epidemiology
Hepatitis B
/ epidemiology
Hepatitis D
/ complications
Hepatitis Delta Virus
/ immunology
Humans
Incidence
Liver Cirrhosis
/ complications
Liver Neoplasms
/ epidemiology
Male
Middle Aged
Tertiary Care Centers
HDV RNA
epidemiology
hepatitis B virus
hepatitis D virus
hepatocellular carcinoma
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
05
09
2018
accepted:
17
12
2018
pubmed:
21
1
2019
medline:
23
7
2020
entrez:
21
1
2019
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) incidence is high in The Gambia, and hepatitis B virus (HBV) infection is the main cause. People coinfected with HBV and hepatitis D virus (HDV) have an even greater risk of HCC and cirrhosis. Using a new HDV quantitative microarray antibody capture (Q-MAC) assay, we evaluated the association between HDV infection and HCC or cirrhosis among participants in The Gambia Liver Cancer Study. In this case-control study, cases had HCC (n = 312) or cirrhosis (n = 119). Controls (n = 470) had no clinical evidence of liver disease and normal serum alpha-foetoprotein. Participants were previously tested for hepatitis B surface antigen (HBsAg); we tested HBsAg+ specimens by HDV Q-MAC, western blot and RNA assays. We evaluated separate cut-offs of the Q-MAC assay for predicting anti-HDV and RNA positivity. Q-MAC correctly identified 29/29 subjects who were western blot-positive (sensitivity = 100%, specificity = 99.4%) and 16/17 who were RNA-positive (sensitivity = 94.1%, specificity = 100%). Compared to controls, cases more often had HBV monoinfection (HBsAg+/HDV RNA-; 54.1% vs 17.0%; odds ratio [OR] = 6.28; P < 0.001) or HBV-HDV coinfection (HBsAg+/HDV RNA+; 3.9% vs 0%; P < 0.001). Risk estimates (for HCC or cirrhosis) based on HDV antibody status and adjusted for covariates (demographics, alcohol, smoking, body mass index, anti-HCV and aflatoxin B1 exposure) yielded consistent results for both HBV monoinfection (adjusted OR = 8.29; 95% confidence interval = 5.74-11.98) and HBV-HDV coinfection (adjusted OR = 30.66; 95% confidence interval = 6.97-134.95). In this Gambian population, HDV Q-MAC had high sensitivity and specificity for both anti-HDV and HDV RNA. HDV infection contributed to the high risk of HCC in The Gambia.
Identifiants
pubmed: 30661282
doi: 10.1111/jvh.13065
pmc: PMC6529252
mid: NIHMS1007596
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-749Subventions
Organisme : Medical Research Council
ID : MC_UP_A900_1120
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Am J Trop Med Hyg. 2000 Jan;62(1):138-41
pubmed: 10761739
Am J Epidemiol. 1976 Feb;103(2):226-35
pubmed: 1251836
Hepatology. 2004 Jan;39(1):211-9
pubmed: 14752840
Int J Cancer. 2004 Jun 20;110(3):374-9
pubmed: 15095302
J Clin Microbiol. 2006 Aug;44(8):3021-4
pubmed: 16891532
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3216-23
pubmed: 18990765
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40
pubmed: 20051970
J Med Virol. 2010 Aug;82(8):1371-8
pubmed: 20572078
J Natl Cancer Inst. 2012 May 16;104(10):790-2
pubmed: 22423008
Clin Infect Dis. 2013 Dec;57(12):1747-50
pubmed: 24051866
J Clin Microbiol. 2014 Feb;52(2):660-2
pubmed: 24478507
Hepatology. 2015 Jun;61(6):1870-9
pubmed: 25677884
World J Hepatol. 2015 Apr 18;7(5):777-86
pubmed: 25914778
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Lancet Glob Health. 2016 Aug;4(8):e559-67
pubmed: 27443781
Hepatology. 2016 Nov;64(5):1483-1494
pubmed: 27530084
Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):580-9
pubmed: 27534692
J Hepatol. 2017 Feb;66(2):297-303
pubmed: 27746337
Hepatology. 2017 Dec;66(6):1739-1749
pubmed: 27880976
J Int AIDS Soc. 2017 Feb 17;19(1):21424
pubmed: 28362065
Lancet Glob Health. 2017 Oct;5(10):e992-e1003
pubmed: 28911765
Hepatology. 2017 Dec;66(6):1716-1718
pubmed: 28961326
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Hepatology. 2018 Apr;67(4):1224-1236
pubmed: 29152762
Semin Liver Dis. 2018 Feb;38(1):66-72
pubmed: 29471567
Lancet. 2018 Mar 3;391(10123):835-836
pubmed: 29508740
J Infect Dis. 2018 May 25;217(12):1902-1906
pubmed: 29800369
J Infect Dis. 1987 May;155(5):931-5
pubmed: 3559292
Am J Public Health. 1998 Jan;88(1):15-9
pubmed: 9584027